LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,093
تعداد مقالات10,030
تعداد مشاهده مقاله27,430,197
تعداد دریافت فایل اصل مقاله7,576,266
Hamed, Rasha, Elkhalk, Seham, Roshdy, Sameh. (1391). The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities. سامانه مدیریت نشریات علمی, 3(Issue 2-3), 45-53.
Rasha Hamdy Hamed; Seham Abd Elkhalk; Sameh Roshdy. "The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities". سامانه مدیریت نشریات علمی, 3, Issue 2-3, 1391, 45-53.
Hamed, Rasha, Elkhalk, Seham, Roshdy, Sameh. (1391). 'The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities', سامانه مدیریت نشریات علمی, 3(Issue 2-3), pp. 45-53.
Hamed, Rasha, Elkhalk, Seham, Roshdy, Sameh. The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities. سامانه مدیریت نشریات علمی, 1391; 3(Issue 2-3): 45-53.

The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities

Middle East Journal of Cancer
مقاله 3، دوره 3، Issue 2-3، مهر 2012، صفحه 45-53    اصل مقاله (317.66 K)
نوع مقاله: Original Article(s)
نویسندگان
Rasha Hamdy Hamed* 1؛ Seham Abd Elkhalk1؛ Sameh Roshdy2
1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2Oncology Center, Mansoura University,Mansoura, Egypt
چکیده
Background: This prospective study assessed the efficacy of neoadjuvant and adjuvant chemotherapy on patients with high risk soft tissue sarcomasof the extremities.Methods: Enrolled patients received the following neoadjuvant chemotherapy: doxorubicin (75 mg/m2) on day1, ifosfamide (2.5 g/m2/d) and mesna (20% of the ifosfamide dose) from days1 to 3, repeated every three weeks for a total of three cycles, followed by surgery and radiotherapy. Patients received an additional three cycles of adjuvant chemotherapy that was the same as the neoadjuvant protocol following completion of radiotherapy.Results: There were 52 patients enrolled in the study, of which 50 were included in data analysis. Neoadjuvant chemotherapy was completed by 90% of enrolled patients and 88% completed all planned chemotherapy. A total of 96% of patients underwent surgery and 92% of these had R0 resections. Postoperative radiotherapy was administered to 96% of patients. The estimated three-year local-regional failure was 10%. Estimated three-year rate for distant disease-free survival was 66% and overall survival was 88%. One patient died with treatment secondary to leukopenic sepsis and respiratory failure. Grades 3-4 toxicities were experienced by 86% of patients of which 84% were grades 3- 4 hematologic toxicities and 38% were grades 3-4 non- hematologic toxicities.Conclusion: The current protocol is feasible and associated with favorable distant disease-free survival, overall survival, and limb preservation. This protocol is tolerable and has a manageable toxicity level.
آمار
تعداد مشاهده مقاله: 2,723
تعداد دریافت فایل اصل مقاله: 495


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب